Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rapamycin + mitoxantrone + etoposide + cytarabine
- Development stage
- Phase 2
- Lead developer
- Merck
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination chemotherapy regimen consisting of rapamycin (also known as sirolimus), mitoxantrone, etoposide, and cytarabine. Rapamycin is an inhibitor of the mammalian target of rapamycin (mTOR), a key regulator of cell growth and proliferation. Mitoxantrone is an anthracenedione that inhibits topoisomerase II, leading to DNA damage and apoptosis. Etoposide is a topoisomerase II inhibitor that induces DNA strand breaks, while cytarabine is a nucleoside analog that inhibits DNA synthesis. This combination has been studied primarily in patients with relapsed or refractory acute myeloid leukemia (AML) to enhance the sensitivity of leukemic cells to chemotherapy by targeting mTOR signaling pathways[1][2][3]. The regimen has shown activity in clinical trials but also significant toxicity.
- Brand names
- None for the combination or for MEC as a regimen
- Other names
- sirolimus + mitoxantrone + etoposide + cytarabineS-MEC
02
Targets
DNA polymerase familyTOP2A (DNA topoisomerase II)Mechanistic target of rapamycin complex 1APC (Activated protein C)
Beyond the preview
Go deeper on rapamycin + mitoxantrone + etoposide + cytarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rapamycin + mitoxantrone + etoposide + cytarabine.